Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer
Stopped Total enrollment number is being lowered
Conditions
- Breast Adenocarcinoma
- HER2/Neu Negative
- Invasive Breast Carcinoma
- Stage IIIC Breast Cancer AJCC v7
- Stage IV Breast Cancer AJCC v6 and v7
Interventions
- DRUG: Eribulin Mesylate
- OTHER: Laboratory Biomarker Analysis
- DRUG: Paclitaxel
- OTHER: Quality-of-Life Assessment
Sponsor
Academic and Community Cancer Research United
Collaborators